These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15021446)

  • 1. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
    Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
    Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Canadian observational study of the optimal method of transition from postmenopausal hormone therapy to raloxifene.
    Lorraine J; Lee B
    J Obstet Gynaecol Can; 2006 Jul; 28(7):583-594. PubMed ID: 16916481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
    Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogens plus raloxifene on endometrial safety and menopausal symptoms--semisystematic review.
    Carneiro AL; de Cassia de Maio Dardes R; Haidar MA
    Menopause; 2012 Jul; 19(7):830-4. PubMed ID: 22549172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.
    Komi J; Lankinen KS; Härkönen P; DeGregorio MW; Voipio S; Kivinen S; Tuimala R; Vihtamäki T; Vihko K; Ylikorkala O; Erkkola R
    Menopause; 2005 Mar; 12(2):202-9. PubMed ID: 15772568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
    Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
    Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
    Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women.
    Lee CC; Kasa-Vubu JZ; Supiano MA
    J Am Geriatr Soc; 2003 May; 51(5):683-8. PubMed ID: 12752845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen.
    Goldstein SR; Johnson S; Watts NB; Ciaccia AV; Elmerick D; Muram D
    Menopause; 2005 Mar; 12(2):160-4. PubMed ID: 15772563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women.
    Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
    Gynecol Endocrinol; 2004 Apr; 18(4):194-8. PubMed ID: 15293890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
    Strickler R; Stovall DW; Merritt D; Shen W; Wong M; Silfen SL
    Obstet Gynecol; 2000 Sep; 96(3):359-65. PubMed ID: 10960626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
    Cohen FJ; Lu Y
    Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
    Smolders RG; Vogelvang TE; Mijatovic V; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P; van der Mooren MJ
    Maturitas; 2002 Feb; 41(2):105-14. PubMed ID: 11836041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
    Carranza-Lira S; Gooch AL; Saldivar N; Osterwalder MS
    Int J Fertil Womens Med; 2007; 52(2-3):93-6. PubMed ID: 18320867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.